If you’ve been eyeing Mesoblast’s chart lately, you’re not alone. The stock has been a talking point for anyone interested in biotech’s dramatic swings, and with good reason. Over just the past 12 months, Mesoblast shares have soared 82.2%, catching the attention of both growth seekers and value hunters. While the last week saw a pullback of 5.7%, and the stock is still down 20.6% year-to-date, those longer-term gains—almost tripling over three years—are tough to ignore. These wild moves are not just random noise; they are rooted in ongoing updates from the company’s product pipeline, strategic partnerships, and developments on regulatory fronts. All of this recent news has influenced how investors perceive Mesoblast’s future potential, shifting risk and reward expectations in real time.

So, is now the right time to get involved? That is where a valuation focus can help put the story into perspective. Mesoblast currently boasts a valuation score of 4 out of 6 by standard measures, suggesting it is undervalued across most checks, but not all. But the real magic is in how we approach these numbers. Up next, we will break down Mesoblast’s valuation using classic methods, plus a twist on how to spot true opportunity even beyond the numbers.

Mesoblast delivered 82.2% returns over the last year. See how this stacks up to the rest of the Biotechs industry.

Approach 1: Mesoblast Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow (DCF) method looks to the future by estimating how much cash a company will generate in the years ahead, then discounts those projections back to today's dollars to find an intrinsic value. This helps investors look beyond short-term swings and focus on underlying business performance.

For Mesoblast, the most recent reported Free Cash Flow is negative, sitting at $-50.7 Million. However, analyst estimates suggest a substantial turnaround ahead, with Free Cash Flow expected to grow to $284.8 Million by 2028 and then continuing a steep upward trajectory. Simply Wall St's extended projections put Mesoblast's Free Cash Flow at over $1.4 Billion by 2035, highlighting ambitious long-term growth potential in the company's pipeline.

Applying these future projections and discounting them appropriately, the DCF model computes an intrinsic value of $32.28 per share. Compared to the current market price, this signals a 91.8% discount, which suggests that the stock appears significantly undervalued by this approach.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Mesoblast.

Story Continues

MSB Discounted Cash Flow as at Oct 2025

Our Discounted Cash Flow (DCF) analysis suggests Mesoblast is undervalued by 91.8%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

Approach 2: Mesoblast Price vs Book

For companies in the biotech sector where profitability is inconsistent, the Price-to-Book (P/B) ratio is often the preferred metric for stock valuation. The P/B ratio compares a company’s market value to its book value, providing insight into how much investors are paying for the assets on the balance sheet. This approach is particularly useful for early-stage or research-focused businesses like Mesoblast, where earnings fluctuate but asset value can indicate underlying potential.

Mesoblast currently trades at a P/B ratio of 3.70x. To put this in perspective, the average P/B ratio among industry peers is 4.55x, while the biotech sector as a whole averages about 4.65x. Mesoblast’s ratio therefore sits comfortably below both the peer group and industry norms, which could hint at undervaluation, especially for investors willing to focus on asset-backed value rather than short-term profits.

But just benchmarking against industry averages and peers isn’t enough. That is where Simply Wall St’s proprietary “Fair Ratio” comes in. This is a tailored valuation multiple calculated based on factors like Mesoblast’s expected growth, profit margins, industry characteristics, market capitalization, and company-specific risks. The Fair Ratio aims to reflect a multiple that fairly prices all these factors, and is a more holistic way to measure whether a stock is truly cheap or expensive compared to blunt averages.

Given that we don’t have a proprietary Fair Ratio much different from Mesoblast’s current P/B, the analysis shows the stock is trading ABOUT RIGHT by this approach.

Result: ABOUT RIGHTASX:MSB PB Ratio as at Oct 2025

PB ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Mesoblast Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is simply the story you tell about a company—your personal take on its future—based on the numbers you expect for fair value, revenue growth, and margins. Narratives connect what is happening in Mesoblast’s business to your financial forecast, making your investment decision more grounded and dynamic.

Narratives are easy to create and share right from Simply Wall St’s Community page, which is a tool trusted by millions of investors. By linking your story to a financial model, Narratives show whether Mesoblast’s fair value is above or below today’s price, helping you decide when it could be a good time to buy, hold, or sell. What makes Narratives especially powerful is how they update automatically as new data, such as earnings or news, arrives.

For example, with Mesoblast, some investors are seeing huge upside and set fair values as high as $35 per share, while others are much more cautious, with estimates closer to $12. Narratives let you see all these perspectives in real time, giving you the confidence to act on what fits your view.

Do you think there's more to the story for Mesoblast? Create your own Narrative to let the Community know!ASX:MSB Community Fair Values as at Oct 2025

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MSB.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments